A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Myelofibrosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts, United States

    Contact: Study coordinator (Gabriella Hobbs, MD) · 866-493-1612
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

    Contact: Study coordinator (Raajit Rampal, MD,PhD) · 646-608-3746
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

    Contact: Study coordinator (Raajit Rampal, MD, PhD) · 646-608-3746
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

    Contact: Study coordinator (Raajit Rampal, MD, PhD) · 646-608-3746
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States

    Contact: Study coordinator (Raajit Rampa, MD, PhD) · 646-608-3746
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

    Contact: Study coordinator (Raajit Rampal, MD, PhD) · 646-608-3746
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Raajit Rampal, MD, PhD) · 646-608-3746
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

    Contact: Study coordinator (Raajit Rampal, MD, PhD) · 646-608-3746
  • Cleveland Clinic, Cleveland, Ohio, United States

    Contact: Study coordinator (Aaron Gerds, MD) · 216-444-6833
Study leads
  • Raajit Rampal, MD, PhD

    Principal Investigator

    Memorial Sloan Kettering Cancer Center